CN104039357A - 胰腺β-细胞增殖的调节 - Google Patents

胰腺β-细胞增殖的调节 Download PDF

Info

Publication number
CN104039357A
CN104039357A CN201280036842.1A CN201280036842A CN104039357A CN 104039357 A CN104039357 A CN 104039357A CN 201280036842 A CN201280036842 A CN 201280036842A CN 104039357 A CN104039357 A CN 104039357A
Authority
CN
China
Prior art keywords
seq
peptide
agent
functional
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280036842.1A
Other languages
English (en)
Chinese (zh)
Inventor
道格拉斯·A·梅尔顿
伊鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CN104039357A publication Critical patent/CN104039357A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
CN201280036842.1A 2011-06-10 2012-06-10 胰腺β-细胞增殖的调节 Pending CN104039357A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161495868P 2011-06-10 2011-06-10
US61/495,868 2011-06-10
US201261613856P 2012-03-21 2012-03-21
US61/613,856 2012-03-21
PCT/US2012/041804 WO2012170977A1 (en) 2011-06-10 2012-06-10 Modulation of pancreatic beta cell proliferation

Publications (1)

Publication Number Publication Date
CN104039357A true CN104039357A (zh) 2014-09-10

Family

ID=47296512

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280036842.1A Pending CN104039357A (zh) 2011-06-10 2012-06-10 胰腺β-细胞增殖的调节

Country Status (7)

Country Link
US (1) US20140303078A1 (https=)
EP (1) EP2717924A4 (https=)
JP (1) JP2014523871A (https=)
CN (1) CN104039357A (https=)
AU (1) AU2012267492A1 (https=)
CA (1) CA2838824A1 (https=)
WO (1) WO2012170977A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922478A (zh) * 2015-08-07 2018-04-17 瑞泽恩制药公司 抗angptl8抗体及其用途

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
CN105073781A (zh) * 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
JP2016517404A (ja) * 2013-03-15 2016-06-16 ユニベルシテ ドゥ ジュネーブ インスリン産生の誘導方法およびその使用
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
US9388430B2 (en) * 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
MX389762B (es) * 2014-03-12 2025-03-20 Neurimmune Holding Ag Novedosos compuestos capaces de antagonizar el daño a las celulas-beta y la tolerancia deteriorada a la glucosa inducidos por el polipeptido amiloide de los islotes (iapp).
EP3822287A1 (en) * 2014-10-03 2021-05-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
WO2017062363A1 (en) * 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
WO2017100540A2 (en) 2015-12-09 2017-06-15 The California Institute For Biomedical Research Relaxin immunoglobulin fusion proteins and methods of use
CA3080148A1 (en) 2017-11-10 2019-05-16 Ngm Biopharmaceuticals, Inc. Angptl8-binding agents and methods of use thereof
US12508428B2 (en) 2023-01-26 2025-12-30 Medtronic, Inc. Respiratory-based cardiac remodeling pacing therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006439A2 (en) * 1997-08-01 1999-02-11 Genset 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN ENDODERM
US20070203083A1 (en) * 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
CN101130768A (zh) * 2006-08-22 2008-02-27 复旦大学 核苷酸分子sr1b及其在制备抗糖尿病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070055056A1 (en) * 1997-03-07 2007-03-08 Rosen Craig A 251 human secreted proteins
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
AU2006223579A1 (en) * 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP1934253A2 (en) * 2005-10-05 2008-06-25 Novo Nordisk A/S Insulin receptor antagonists and related compositions, uses and methods
JP5421109B2 (ja) * 2006-09-13 2014-02-19 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 低カルボキシル化／非カルボキシル化オステオカルシンはベータ細胞増殖、インスリン分泌、インスリン感受性、耐糖能を増加させ、体脂肪量を減少させる
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006439A2 (en) * 1997-08-01 1999-02-11 Genset 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN ENDODERM
US20070203083A1 (en) * 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
CN101130768A (zh) * 2006-08-22 2008-02-27 复旦大学 核苷酸分子sr1b及其在制备抗糖尿病药物中的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922478A (zh) * 2015-08-07 2018-04-17 瑞泽恩制药公司 抗angptl8抗体及其用途

Also Published As

Publication number Publication date
EP2717924A4 (en) 2015-04-22
EP2717924A1 (en) 2014-04-16
WO2012170977A1 (en) 2012-12-13
AU2012267492A1 (en) 2014-01-09
US20140303078A1 (en) 2014-10-09
JP2014523871A (ja) 2014-09-18
CA2838824A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
CN104039357A (zh) 胰腺β-细胞增殖的调节
AU779745B2 (en) Methods and reagents for treating glucose metabolic disorders
CN102389413B (zh) 用于治疗糖尿病的组合物及其应用
Koya et al. Reversal of Streptozotocin-Induced Diabetes in Mice by Cellular Transduction With Recombinant Pancreatic Transcription Factor Pancreatic Duodenal Homeobox-1: A Novel Protein Transduction Domain–Based Therapy
CN103648531A (zh) 用于预防或治疗代谢综合症的方法
US20170157110A1 (en) Methods for inducing insulin production and uses thereof
KR20170023066A (ko) 글루카곤 수용체 길항 항체를 이용한 제 1 형 당뇨병의 치료 방법
JP2019065025A (ja) 糖尿病を治療および／または発症を制限するための方法
JP2023015235A (ja) 新規なｉｇｆｒ様レセプター及びその使用
JP2016508509A (ja) 糖尿病を治療するための改変されたｉｎｇａｐペプチド
US11999776B2 (en) IGFR-like 2 receptor and uses thereof
CN116392500B (zh) microRNA及其在诊断和治疗中的用途
CN113425843B (zh) 一种gp73抑制剂在制备治疗糖尿病的药物中的应用
US12583928B2 (en) Antibodies against IGFR-like receptor and uses thereof
WO2021179106A1 (zh) 一种gp73抑制剂在制备治疗糖尿病的药物中的应用
EP1902729A1 (en) Int6 PROTEIN INVOLVED IN HYPOXIA STRESS INDUCTION AND USE THEREOF
US20200405773A1 (en) Promoting and protecting functional beta cell mass by syntaxin 4 enrichment
Presley Novel Roles of Gastrin and Cholecystokinin in Islet Beta Cell Proliferation
Lam AIBIS abstracts
KR20110123624A (ko) 췌장세포 재생 확인용 바이오마커 및 이의 이용

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140910